Home
Learn More
Features & Pricing
Success Stories
Contact Us
Search Archives
Journalists
Submit Release
January 24, 2009
 
Industry Categories  
News by Country  
News by MSA  
Today's News  
Browse by Day  
PR Trackbacks™  
Featured Videos  
ViewNews™  
eBook Digests  
RSS  
PRWeb, a leader in online news and press release distribution, has been used by more than 40,000 organizations of all sizes to increase the visibility of their news, improve their search engine rankings and drive traffic to their Websites.
 
Close Move
All Press Releases for November 5, 2007 Subscribe to this News Feed    
 

Heart Bypass Surgery Drug Causing Kidney/Renal Failure Suspended; Anapol Schwartz Attorney -- Representing Victims -- Says Situation Could Be Next Baycol

PHILADELPHIA (Business Wire EON/PRWEB ) November 5, 2007 -- According to James Ronca of law firm Anapol, Schwartz, Weiss, Cohan, Feldman & Smalley, P.C., Bayer AGs announcement today that it would suspend sales of blood-clotting drug Trasylol®, could lead to a situation in which it becomes the next Baycol. Trasylol® is used in coronary artery bypass graft (CABG) procedures and found to cause kidney/renal failure.

Ronca represents more than a dozen families and alleged victims in this growing area of litigation, and recently filed a Trasylol® lawsuit a wrongful death complaint in Philadelphia.

This should have been prevented. Again, we have an example of a highly expensive drug that was put on the market and pushed for too broad of a patient population, before enough studies were done on its safety, and when there were less expensive competing drugs available, says Ronca, who leads advocacy initiatives to raise awareness about Trasylols® side effects.

Trasylol® is administered by an anesthesiologist during CABG surgery to limit bleeding, and affected patients typically experience kidney/renal failure symptoms within 48 hours. Many, however, are unaware they have received the drug, complicating diagnosis.

This announcement should educate the public about the dangers associated with this drug, and open the door for victims, and those who dont realize they are victims, to receive remuneration for their injuries, stresses Ronca, who has served as counsel to victims in product liability cases involving Baycol, LOTRONEX, hormone replacement therapy and breast implants.

Anapol, Schwartz, Weiss, Cohan, Feldman & Smalley is a personal injury firm with law offices in Philadelphia, Reading, Media, Fairless Hills and Haverford, Pa., as well as Cherry Hill, N.J. The firm is a multi-faceted practice with a tradition of excellence in medical malpractice law, pharmaceutical mass tort, toxic tort, class actions, products liability, automobile, securities and wrongful termination litigation. Since its founding in 1977, the firm has grown to over 30 attorneys, and compiled a record of success exceptional among its peers.

Post Comment:
Trackback URL: http://www.prweb.com/pingpr.php/TWFnbi1aZXRhLU1hZ24tWmV0YS1UaGlyLVplcm8=

Technorati Tags

Bookmark -  Del.icio.us | Furl It | Technorati | Ask | MyWeb | Propeller | Live Bookmarks | Newsvine | TailRank | Reddit | Slashdot | Digg | Stumbleupon | Google Bookmarks | Sphere | Blink It | Spurl


OPTIONS
Printer Friendly Version
Download PDF Version
Download Reader Version
BlogThis
ShareIt

Share The News

Submit this press release easily to any of these major bookmarking and social media sites.

CONTACT INFORMATION

Anapol, Schwartz, Weiss, Cohan, Feldman & Smalley, P.C.
by
Star Toplin
Jennifer Wasilisin, 215-793-4666
jenniferw@toplin.com

ATTACHED FILES

There are no multimedia files attached to this release. If this is your release, you may add images or other multimedia files through your PRWeb News Management Console.

ABOUT PRESS RELEASES
If you have any questions regarding information in these press releases please contact the company listed in the press release. Please do not contact PRWeb. We will be unable to assist you with your inquiry. PRWeb disclaims any content contained in these release. Our complete disclaimer appearshere.
 
Disclaimer: If you have any questions regarding information in these press releases please contact the company listed in the press release.
Please do not contact PRWeb®. We will be unable to assist you with your inquiry.
PRWeb® disclaims any content contained in these releases. Our complete disclaimer appears here.

© Copyright 1997-2009, Vocus PRW Holdings, LLC.
Vocus, PRWeb and Publicity Wire are trademarks or registered trademarks of Vocus, Inc. or Vocus PRW Holdings, LLC.

Terms of Service | Privacy Policy | Copyright